Bristol Myers Squibb beats profit estimates

PARAGRAPH 1 --- What happened: Bristol Myers Squibb (BMY) reported first-quarter profits on April 30, 2023, exceeding Wall Street estimates. The drugmaker's performance was driven by strong sales of its blood thinner Eliquis and newer cancer medicines. Notably, Vertex Pharmaceuticals (VRTX) also posted robust Q1 results on May 4, 2023, with a near eight-fold surge in sales of its new cystic fibrosis treatment.

PARAGRAPH 2 --- Market impact: BMY's robust performance pushed its stock up 4% on April 30, 2023, reflecting investor confidence in the company's growth portfolio. This includes Eliquis, Opdivo, and Yervoy, which continue to drive revenue growth. VRTX's impressive results also boosted the biopharma sector, with investors eyeing potential growth in rare disease treatments.

PARAGRAPH 3 --- What to watch next: Investors should monitor BMY's upcoming earnings releases, with Q2 results expected on August 1, 2023. Additionally, the market will closely watch the U.S. Food and Drug Administration's (FDA) decision on VRTX's new CF drug, Trikafta, for patients aged 6 to 11 years, expected by June 24, 2023. Lastly, BMY's pipeline progress, particularly in immuno-oncology, will be a key focus for investors in the coming months.